India, Aug. 12 -- Insmed Inc. (INSM) announced Tuesday that the U.S. Food and Drug Administration approved first-in-class BRINSUPRI (brensocatib 10 mg and 25 mg tablets), an oral, once-daily treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and children 12 years and older.
INSM closed Tuesday regular trading at $122.00 up $9.11 or 8.07%. In the after-hours trading the stock further gained $0.03 or 0.02%.
BRINSUPRI is the first and only FDA-approved treatment for non-cystic fibrosis bronchiectasis or NCFB, giving hundreds of thousands of patients and clinicians across the U.S. an option to manage this chronic and progressive disease that can lead to permanent lung damage and lung function decline.
googletag.cmd.push(functi...